AZN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

15.42B

+3.56%

1.085

+3.85%

14.55B

+7.05%

1.260

+1.2%

14.99B

+3.68%

1.100

+1.38%

Estimates Revision

The market is revising Upward the revenue expectations for AstraZeneca PLC (AZN) for FY2025, with the revenue forecasts being adjusted by 0.42% over the past three months. During the same period, the stock price has changed by 10.11%.

Revenue Estimates for FY2025

Revise Upward

+0.42%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.41%

In Past 3 Month

Stock Price

Go Up

+10.11%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 99.67 USD with a low forecast of 95.00 USD and a high forecast of 103.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

95.00

Averages

99.67

High

103.00

Current: 0.000

Low

95.00

Averages

99.67

High

103.00

Barclays

James Gordon

NULL -> Overweight

upgrade

2026-01-06

New

Reason

Barclays

James Gordon

Price Target

2026-01-06

New

upgrade

NULL -> Overweight

Reason

Barclays analyst James Gordon raised the firm's price target on AstraZeneca to 16,500 GBp from 14,000 GBp and keeps an Overweight rating on the shares.

Goldman Sachs

downgrade

2026-01-05

New

Reason

Goldman Sachs

Price Target

2026-01-05

New

downgrade

Reason

Goldman Sachs analysts removed AstraZeneca from the firm's European Conviction List as part of its monthly update.

HSBC

Buy

upgrade

$95 -> $108

2025-12-10

Reason

HSBC

Price Target

$95 -> $108

2025-12-10

upgrade

Buy

Reason

HSBC raised the firm's price target on AstraZeneca to $108 from $95 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

TD Cowen

Buy

upgrade

$95 -> $105

2025-12-09

Reason

TD Cowen

Price Target

$95 -> $105

2025-12-09

upgrade

Buy

Reason

TD Cowen raised the firm's price target on AstraZeneca to $105 from $95 and keeps a Buy rating on the shares. The firm said the company has promising new products and pipeline and participates in many large, high-growth markets. Numerous events are upcoming for investors to assess progress. EPS growth appears to be above industry average, with upside possible.

JPMorgan

NULL -> Overweight

upgrade

2025-12-08

Reason

JPMorgan

Price Target

2025-12-08

upgrade

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on AstraZeneca to 16,000 GBp from 14,000 GBp and keeps an Overweight rating on the shares.

JPMorgan

NULL

Overweight

maintain

2025-12-08

Reason

JPMorgan

Price Target

2025-12-08

maintain

NULL

Overweight

Reason

JPMorgan raised the firm's price target on AstraZeneca to 16,000 GBp from 14,000 GBp and keeps an Overweight rating on the shares. JPMorgan also added AstraZeneca to its European Analyst Focus List. The firm adjusted ratings in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.

Valuation Metrics

The current forward P/E ratio for AstraZeneca PLC (AZN.O) is 18.07, compared to its 5-year average forward P/E of 17.10. For a more detailed relative valuation and DCF analysis to assess AstraZeneca PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

17.10

Current PE

18.07

Overvalued PE

20.88

Undervalued PE

13.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

13.88

Current EV/EBITDA

14.29

Overvalued EV/EBITDA

15.12

Undervalued EV/EBITDA

12.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.22

Current PS

4.62

Overvalued PS

4.61

Undervalued PS

3.83

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 166.61% over the last quarter.

Sold

Bought

Congress Trading

Congress areSelling! The selling amount has increased100%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AZN News & Events

Events Timeline

No data

News

9.0

01-06Benzinga

AstraZeneca Reports Phase 3 TULIP-SC Results for Saphnelo, 56.2% of Patients Show Improvement

2.0

01-02Barron's

Healthcare and Bank Stocks Experienced Remarkable Growth in 2025, with Continued Gains Expected This Year.

7.5

01-02Yahoo Finance

Healthcare Stocks Rally Since June 2025, Outperforming Tech Sector

People Also Watch

Frequently Asked Questions

What is AstraZeneca PLC (AZN) stock price today?

The current price of AZN is 94.01 USD — it has decreased -1.21 % in the last trading day.

What is AstraZeneca PLC (AZN)'s business?

AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.

What is the price predicton of AZN Stock?

What is AstraZeneca PLC (AZN)'s revenue for the last quarter?

AstraZeneca PLC revenue for the last quarter amounts to 15.19B USD, increased 11.99 % YoY.

What is AstraZeneca PLC (AZN)'s earnings per share (EPS) for the last quarter?

AstraZeneca PLC. EPS for the last quarter amounts to 1.62 USD, increased 78.02 % YoY.

What changes have occurred in the market's expectations for AstraZeneca PLC (AZN)'s fundamentals?

How many employees does AstraZeneca PLC (AZN). have?

AstraZeneca PLC (AZN) has 94300 emplpoyees as of January 09 2026.

What is AstraZeneca PLC (AZN) market cap?

Today AZN has the market capitalization of 291.48B USD.